Why does one drug, Kaydeco, cost €232,000?
As more medicines costing hundreds of thousands of euro are launched, can the state afford to pay? And is Big Pharma pricing drugs fairly? Susan Mitchell reports.
It is one of the oldest debates in economics: what is the difference between what something costs and what it is worth? In Ireland, that debate has been given new urgency by Kalydeco, a drug used to treat cystic fibrosis.
Kalydeco is a revolutionary drug that will transform the lives of patients who have at least one copy of the G551D mutation - the so-called Celtic gene mutation.
The manufacturer, Vertex Pharmaceuticals, priced Kayldeco...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
*New subscribers only
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Unlimited Access for 2 Years
Get a Business Account for you and your team